The Vaginal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vaginal Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued products.
GlobalData tracks 47 drugs in development for Vaginal Cancer by 38 companies/universities/institutes. The top development phase for Vaginal Cancer is phase ii with 28 drugs in that stage. The Vaginal Cancer pipeline has 47 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Vaginal Cancer pipeline products market are: AstraZeneca, Bristol-Myers Squibb and SQZ Biotechnologies.
The key targets in the Vaginal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Human Papillomavirus Protein E7 (E7), and Human Papillomavirus Protein E6 (E6).
The key mechanisms of action in the Vaginal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with five drugs in Phase II. The Vaginal Cancer pipeline products include 14 routes of administration with the top ROA being Intravenous and ten key molecule types in the Vaginal Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Vaginal Cancer overview
Vaginal cancer is a rare cancer that occurs in the vagina. Symptoms includes watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, and vaginal bleeding. Risk factors include age, smoking, HIV infection, and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy, and chemotherapy.
For a complete picture of Vaginal Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
